Rani Therapeutics (RANI)
(Delayed Data from NSDQ)
$2.93 USD
+0.06 (2.09%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.87 -0.06 (-2.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMRani Therapeutics Holdings, Inc. (RANI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.57 | $15.00 | $8.00 | 303.14% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Rani Therapeutics Holdings, Inc. comes to $11.57. The forecasts range from a low of $8.00 to a high of $15.00. The average price target represents an increase of 303.14% from the last closing price of $2.87.
Analyst Price Targets (7 )
Broker Rating
Rani Therapeutics Holdings, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
6/13/2024 | Maxim Group | Michael Okunewitch | Not Available | Strong Buy |
5/16/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
5/10/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
5/9/2024 | BTIG | Julian Harrison | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/27/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $11.57 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.29 |